

Indication¹: SHINGRIX is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in: adults 50 years of age or older, and adults 18 years of age or older at increased risk of HZ. **Dosing and administration¹:** The primary vaccination schedule consists of two doses of 0.5 mL each; an initial dose followed by a second dose 2 to 6 months later. For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and who would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose. SHINGRIX is for intramuscular injection only, preferably in the deltoid muscle. **Safety¹:** In pivotal trials, very common ($\geq 10\%$) solicited local adverse reactions and solicited general adverse events were pain, redness, and swelling at the injection site; and myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms, respectively. SHINGRIX is a non-live vaccine and is not contraindicated in patients who are immunocompromised. As with other vaccines, an adequate immune response may not be elicited in these individuals. The administration of SHINGRIX to immunocompromised patients should be based on careful consideration of potential benefits and risks.

For more information on GSK vaccines and medicines register now at
<https://gskpro.com/en-au>

Please review full SHINGRIX Product Information before prescribing. Product Information
can be accessed at www.gsk.com.au/shingrix or by scanning the QR code to the right.



▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems


PBS INFORMATION: SHINGRIX is listed on the National Immunisation Program (NIP) for Aboriginal and Torres Strait Islander adults aged ≥ 50 years, for all individuals aged ≥ 65 years and for adults aged ≥ 18 years with some immunocompromising medical risk conditions. Refer to NIP schedule or your State or Territory Health department.

Reference: 1. SHINGRIX Approved Product Information

This educational activity was initiated, developed and organised by GSK. This is an educational event for your professional development. Therefore, accompanying persons such as family members or friends are not invited to attend.

We, GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding 'SHINGRIX: optimising shingles prevention in your practice'. We may disclose your personal information to third parties we use in the ordinary operations of our business, including our affiliates and third parties located overseas. If we do not collect your personal information, we may be unable to provide you with all of our services. Our privacy policy can be found at <http://au.gsk.com/en-au/privacy-policy/> and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd, Level 4, 436 Johnston Street, Abbotsford, 3067.

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. © 2024 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd, ABN 47 100 162 481, Melbourne, VIC.
PM-AU-SGX-EML-230031 Date of approval: January 2024.



Hypothetical patient, based on some patients' description of shingles pain. Symptoms may vary and not everyone will experience these symptoms. SHINGRIX is contraindicated in people with hypersensitivity to the active substances or to any component of the vaccine.¹

SHINGRIX:

optimising shingles prevention in your practice

Join us to learn more about shingles and SHINGRIX, a vaccine
to help prevent shingles in your patients ≥ 50 years of age.¹

We are pleased to invite you to an engaging meeting which aims to enhance your knowledge of **SHINGRIX** and optimising shingles prevention in your practice



Meeting Details

Date 26th of June 2024
Time 6:30pm-8:30 pm
Venue International Hotel, Corner of Sturt Hwy & Lake Albert Rd, Wagga Wagga, NSW, 2650

RSVP by

Agenda (30 minute presentation + Q&A)

6:30 - 6:45 pm Arrival, registration and entree is served
6:45 - 7:45 pm Presentation
7:45 - 8:15 pm Q&A and dinner is served
8:15 - 8:30 pm Dessert is served and close

Speaker

Dr Craig Haifer - Gastroenterologist and Hepatologist MBBS (Hons), PhD, FRACP

Dr Craig Haifer is a Staff Specialist Gastroenterologist at St Vincent's Hospital and Senior Lecturer (Conjoint) - University of New South Wales.

Dr Haifer has completed a PhD in the gut microbiome and manipulation with faecal transplantation and became a Fellow of the Royal Australian College of Physicians in Gastroenterology and Hepatology in 2017.

Dr Haifer specialises in all aspects of gastroenterology and hepatology including Crohn's disease, ulcerative colitis, gut microbiome, faecal microbiota transplantation (FMT), bowel cancer screening, irritable bowel syndrome, and liver disorders. He performs procedures at Double Bay Day Hospital, St Vincent's Hospital and Riverina Day Surgery (Wagga Wagga) including gastroscopy, colonoscopy, and capsule endoscopy; and is accredited under the International Bowel Ultrasound Group (IBUS) to perform bowel ultrasound.

Dr Haifer is at the forefront of research and clinical trials, spearheading local and international initiatives through St Vincent's Hospital.

Registration Details

Please register your attendance at this meeting by scanning the QR code below. Alternatively, to register directly with your representative, or for any questions regarding this meeting, please contact your representative via the details below.

SCAN



Email Daniel.x.tetreault@gsk.com



Phone 0428 234 757



TO REGISTER